Preoperative serum cystatin-C as a potential biomarker for prognosis of renal cell carcinoma

Shengjie Guo1*, Yunfei Xue2☯, Qiuming He1☯, Xiaobo He3, Kunbin Guo4, Pei Dong1, Kai Yao1, Guangwei Yang2, Dong Chen1, Zaishang Li1, Xiangdong Li1, Zike Qin1, Zhuowei Liu1, Wenjie Cheng5, Chao Guo6, Meng Zhang2, Hui Han1*, Fangjian Zhou1*

1 Department of Urology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China, 2 Medicine school of Sun Yat-Sen University, Guangzhou, China, 3 Department of Medical Oncology, the Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, China, 4 Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou, China, 5 Department of Urology, the Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, China, 6 The Jiangcheng Branch of Yangjiang People’s Hospital, Yangjiang, Guangdong, China

☯ These authors contributed equally to this work.
* hanhui@sysucc.org.cn (HH); zhoufj@sysucc.org.cn (FZ)

Abstract

Purpose
The prognostic value of serum cystatin-C (Cys-C) in renal cell carcinoma (RCC) remains unknown. The purpose of this study is to explore the prognostic value of Cys-C for RCC patients.

Patients and methods
The levels of preoperative Cys-C, creatinine (CRE) and estimated glomerular filtration rate (e-GFR) were retrospectively collected in 325 RCC patients undergoing surgery. The cutoff values of Cys-C, CRE and e-GFR were determined by the standardized Cutoff Finder algorithm. The receiver operating characteristic (ROC) curve and pairwise comparison were performed to compare the three variables. Univariate and multivariate Cox regression analyses were performed to investigate the prognostic value of serum Cys-C in RCC.

Results
Based on the analysis of Cutoff Finder algorithm, ROC curve and pairwise comparison, the preoperative Cys-C was superior to CRE and e-GFR as a predictive factor in RCC. Multivariate Cox regression analyses showed that high preoperative Cys-C (>1.09 mg/L) was significantly associated with shorter overall survival (OS) in all RCC patients (hazard ratio [HR], 1.59; P = 0.012), patients at pT1-2 (P<0.001), pN0 (P<0.001) and pM0 stages (P<0.001). Moreover, Multivariate Cox regression analyses also showed that in the 306 patients without metastasis, high preoperative Cys-C was also associated with shorter disease-free survival (DFS) (HR, 3.50; P = 0.013).
Conclusions
An elevated preoperative Cys-C level was demonstrated to be related with worse survival in patients with RCC. Measuring preoperative serum Cys-C might be a simple way for finding poor prognostic patients and patients with elevated preoperative Cys-C level should be more closely followed up.

Introduction
Renal cell carcinoma (RCC) is one of the most common malignant urogenital tumors [1, 2]. In recent years, RCC can be detected more frequently at early stage because of increased use of imaging techniques including ultrasound and computed tomography (CT) [3, 4]. Despite more RCC has been diagnosed at early stage, the disease death rate is still rising. Approximately 20~30% of patients with localized disease after radical or partial nephrectomy will later develop metastatic disease [5] due to lack of curative therapies for metastatic RCC. Majority of patients at advantageous stage will die from cancer. There is an urgent need for prognostic factor to predict high risk of recurrent or metastatic patients who will be closely followed up. Although TNM [6] and Fuhrman’s nuclear grading systems [7] are most useful prognostic factors, they are still not perfect [8]. Other well-known prognostic factors include lymphocytic infiltration, necrosis and histological subtype [8]. Due to the insufficiency of these prognostic factors, new factors including clinical and laboratory indicators have started to be considered.

Cystatin-C (Cys-C) is a cysteine protease inhibitor produced by nearly all nucleated cells and excreted into the bloodstream [9]. Cys-C has multiple biological functions including controlling extracellular proteolysis via inhibition of cysteine peptidases, modulating immune system and exerting antibacterial and antiviral activities [9, 10]. Cys-C is freely filtered by the glomerulus, and reabsorbed and metabolized by the proximal tubules. Therefore, it is considered an accurate endogenous marker of GFR in various types of kidney diseases [11, 12]. As a secreted cysteine protease inhibitor, Cys-C may inhibit cathepsins (B, D, H, L and S) and other human lysosomal cysteine proteases [13]. By inactivating cathepsin protease activity, Cys-C is served as an inhibitor of cancer cell invasion and metastasis [14, 15]. Abnormal serum levels of Cys-C or cathepsin B/cystatin C complex have been suggested as diagnostic and prognostic indicators for cancers of skin, breast, colon and lung [16].

However, little is known about the expression of Cys-C in RCC. The purpose of this research was to analyze the prognostic value of serum Cys-C in patients with surgical RCC.

Patients and methods
Patients
398 patients who were diagnosed with RCC and treated with resection of primary tumor at Sun Yat-sen University Cancer Center (SYSUCC) between September 2009 and January 2013 were retrospectively enrolled in the study. To ensure that data were collected objectively and accurately, patient inclusion criteria were Age ≥ 18 years, and no previous or coexisting tumor. The following exclusion criteria were used: patients with a history of anticancer therapy, or other concurrent concomitant diseases (including diabetes, uncontrolled hypertension, inflammation, and infection), or insufficient biochemical test results, or survival data. Among them, 325 patients were enrolled in this study. The study was approved by the Institutional Review Board of SYSUCC and performed in accordance with the ethical standards of the
World Medical Association Declaration of Helsinki. All included patients provided written informed consent and their information were recorded and registered in our cancer registry system. The authenticity of this article has been validated by uploading the key raw data onto the Research Data Deposit public platform (www.researchdata.org.cn), with the approval RDD number as RDDA2017000174.

Patients follow-up

Follow-up evaluations were carried out included physical, laboratory examination and radiological examinations referring to the National Comprehensive Cancer Network (NCCN) clinical practice guidelines. In addition, all patients were also followed up via telephone interviews. The last follow-up was completed in November 1, 2015, and after that, the whole data was analyzed. The primary endpoint was overall survival (OS), which was defined as the interval between surgery and last follow-up or death from all causes. The secondary endpoint was disease free survival (DFS), which was calculated as the interval between surgery and last follow-up or recurrence.

Statistical analysis

Continuous variables and categorical variables were presented as median (range), and number (percentage), respectively. Percentage differences between groups were compared with χ² test or Fisher’s exact test. Continuous data were compared using Mann-Whitney test. Relationship between variables was determined using two-sided Spearman’s correlation coefficient. Estimated glomerular filtration rate (e-GFR) was calculated by the Cockcroft-Gault [17] adjusted for body surface area by normalizing the output per 1.73 m² of body surface area. The optimal cutoff values of preoperative serum Cys-C, creatinine (CRE) and e-GFR were determined using a web-based R software engineered and designed by Budczies et al [18] (http://molpath.charite.de/cutoff/). The predictive value of the established model was assessed using the area under the receiver operating characteristic (ROC) curve (AUC), and the pairwise comparison of AUC values of significant biomarkers was carried out using z statistical method. The associations of preoperative serum Cys-C with pT-stage, pN-stage and pM-stage were assessed using non-parametric analysis of variance (ANOVA). OS and DFS were measured using Kaplan-Meier curves and log-rank test. Variables with prognostic significance for survival were identified using univariate Cox regression analyses and further analyzed using multivariate Cox regression analysis to test their independence. Hazard ratios (HRs) estimated from the Cox analysis were reported as relative risks with corresponding 95% confidence intervals (CIs). All statistical analyses were performed using SPSS21.0 software (IBM, Armonk, NY) and MedCalc (MedCalc Software, Ostend, Belgium). All tests were two-sided and a P value <0.05 was considered statistically significant.

Results

Clinicopathologic characteristics

The 325 enrolled patients had mean age of 51 years old. Among them, 222 (68.30%) were males. In addition, 260 (80.00%), 20 (6.20%) and 45 (13.80%) were pathologically diagnosed as clear cell carcinoma, papillary type and other types, respectively; 227 (69.80%), 46 (14.2%), 26 (8.00%) and 26 (8.00%) were staged in I, II, III and IV, respectively. Table 1 shows their baseline characteristics.

The mean follow-up time was 48.74 months. Mean DFS and OS were 67.25 and 66.66 months, respectively.
Table 1. Clinicopathological characteristics of patients.

| Characteristics                      | Value  |
|--------------------------------------|--------|
| Age, (years) (median)                | 51     |
| Range                               | 18–84  |
| Gender                              |        |
| Male                                | 222 (68.30%) |
| Female                              | 103 (31.70%) |
| BMI, (kg/m$^2$) (median)            | 23.44  |
| Range                               | 15.41–38.76 |
| Fuhrman grade                       |        |
| I                                    | 47 (14.50%) |
| II                                   | 156 (48.00%) |
| III                                  | 37 (11.40%) |
| IV                                   | 7 (2.20%) |
| unknown                             | 78 (24.00%) |
| Pathological types                  |        |
| Clear cell carcinoma                | 260 (80.00%) |
| Papillary carcinoma                 | 20 (6.20%) |
| Others                              | 45 (13.80%) |
| pTNM stage                          |        |
| I                                    | 227 (69.80%) |
| II                                   | 46 (14.20%) |
| III                                  | 26 (8.00%) |
| IV                                   | 26 (8.00%) |
| pT-stage                            |        |
| pT1                                  | 235 (72.30%) |
| pT2                                  | 53 (16.30%) |
| pT3                                  | 26 (8.00%) |
| pT4                                  | 11 (3.40%) |
| pN-stage                            |        |
| pN0                                  | 305 (93.80%) |
| pN1                                  | 20 (6.20%) |
| pM-stage                            |        |
| pM0                                  | 306 (94.20%) |
| pM1                                  | 19 (5.80%) |
| Preoperative ALP, (U/L) (median)     | 71.90  |
| Range                               | 16.00–419.00 |
| Preoperative TP, (g/L) (median)      | 72.67  |
| Range                               | 29.65–93.46 |
| Preoperative UA, (μmol/L) (median)   | 358.30 |
| Range                               | 112.60–616.30 |
| Preoperative CRE, (μmol/L) (median)  | 75.40  |
| Range                               | 38.10–221.90 |
| Preoperative Cystatin-C, (mg/L) (median) | 0.98 |
| Range                               | 0.50–2.96 |
| Preoperative e-GFR, (mL/min/1.73 m$^2$) (median) | 78.69 |
| Range                               | 16.31–144.31 |

Abbreviation: BMI: body mass index; ALP: alkaline phosphatase; TP: total protein; UA: uric acid; CRE: creatinine; e-GFR: estimated glomerular filtration rate.

https://doi.org/10.1371/journal.pone.0178823.t001
The relationship of serum Cys-C, CRE or e-GFR with predictor of prognosis of RCC patients

Serum Cys-C is considered a potential marker of renal function, thus, its relationship with serum CRE and e-GFR were analyzed for predicting the prognosis of RCC patients. The results showed that preoperative serum CRE and e-GFR levels were positively and negatively correlated to Cys-C as determined by Spearman’s correlation coefficient test ($r = 0.365, P < 0.001$; and $r = -0.416, P < 0.001$, respectively). In addition, preoperative CRE and e-GFR levels were negatively correlated ($r = -0.718, P < 0.001$). Analysis using the Cutoff Finder showed the recommended cutoff values of preoperative serum Cys-C, CRE and e-GFR for evaluating OS were 1.09, 44.9 and 77.16, respectively (Fig 1). In addition, ROC curve analysis of the three indicators showed that preoperative serum Cys-C was significant (AUC = 0.69, $P < 0.001$), but not CRE (AUC = 0.52, $P = 0.594$) and e-GFR (AUC = 0.55, $P = 0.325$) (Table 2). Furthermore, pairwise comparisons of the three biomarkers showed that preoperative serum Cys-C is a better index than CRE and e-GFR for assessing the prognosis of RCC patients (Table 3).

Overall, based on the cutoff value of serum Cys-C, these patients were divided into low serum Cys-C ($\leq 1.09$ mg/L) and high serum Cys-C (>1.09 mg/L) groups, respectively.

The relationship between clinicopathological characteristics and preoperative serum Cys-C

The clinicopathological characteristics in each subgroup are described in Table 4. Patients with low preoperative serum Cys-C were significantly younger ($P < 0.001$) and had lower preoperative ALP, CRE and UA levels but higher preoperative e-GFR. In addition, preoperative serum Cys-C level was associated with gender ($P = 0.008$), pT-stage ($P < 0.001$), pN-stage ($P = 0.036$), pM-stage ($P = 0.020$), pTNM-stage ($P < 0.001$), Fuhrman grade ($P = 0.005$) and pathological types ($P = 0.016$), but not BMI ($P = 0.592$) and preoperative TP ($P = 0.481$). Moreover, as a continuous variable, preoperative serum Cys-C level was significantly higher in RCC patients at pT3-4 and pM1 than RCC patients at pT1-2 ($P < 0.001$) and pM0 ($P = 0.005$), respectively, but similar among RCC patients at different pN-stage ($P = 0.052$). In addition, the preoperative e-GFR level was lower in patients with pT3-4 stage than pT1-2 stage ($P < 0.001$) and the preoperative CRE level was higher in patients with pT3-4 stage ($P = 0.015$). The preoperative CRE and e-GFR levels were not statistically significant for the subgroup of the pN and pM stage. The details were depicted in Fig 2.

The relationship of preoperative serum Cys-C with OS of RCC patients

Univariate Cox proportional hazards regression model analysis based on the cut-off levels of serum Cys-C showed that low preoperative serum Cys-C was associated with better OS ($P < 0.001$). In addition, BMI, Fuhrman-grade, pTNM stage, pT-status, pN-status, pM-status and ALP were also remained clinically and statistically significant predictors of prognosis (Table 5). Multivariate Cox regression analysis showed that low serum Cys-C was a significant independent predictor favorable for OS (HR, 1.59; $P = 0.012$). In addition, pN-status and pM-status also remained clinically and statistically significant predictors of prognosis (Table 5).

To further investigate the prognostic significance of serum Cys-C level in RCC patients, the whole cohort was compared using Kaplan-Meier method and log-rank test. Patients with Cys-C $\leq 1.09$ mg/L ($n = 216$) showed a significantly better OS than patients with serum Cys-C >1.09 mg/L ($n = 109$) (Cys-C $\leq 1.09$ mg/L vs. >1.09 mg/L, mean OS: 69.86 vs. 55.20 months, respectively, $P < 0.001$, Fig 3A). We also evaluated the prognostic influence of serum Cys-C level in the subgroups based on the pT-status, pN-status, pM-status, respectively. Patients with low
Fig 1. Hazard ratios and cutoff values of independent factors for overall survival of patients with renal cell carcinoma. (A) Preoperative serum cystatin C; (B) Creatinine (CRE); and (C) estimated glomerular
serum Cys-C level had significantly longer OS than compared patients with high serum Cys-C level in the stage I-II subgroup (n = 204, Cys-C ≤ 1.09 mg/L vs. > 1.09 mg/L, mean OS: 72.10 vs. 60.96 months, respectively, P = 0.001, Fig 4A), T1-2 subgroup (n = 288, Cys-C ≤ 1.09 mg/L vs. > 1.09 mg/L, mean OS: 70.99 vs. 58.12 months, respectively, P < 0.001, Fig 4C), and N0 subgroup (n = 305, Cys-C ≤ 1.09 mg/L vs. > 1.09 mg/L, mean OS: 71.27 vs. 57.99 months, respectively, P < 0.001, Fig 4E). However, the OS was not significantly different in RCC patients at stage III-IV subgroup (n = 52, Cys-C ≤ 1.09 mg/L vs. > 1.09 mg/L, mean OS: 39.67 vs. 39.85 months, respectively, P = 0.936, Fig 4B), T3-4 subgroup (n = 37, Cys-C ≤ 1.09 mg/L vs. > 1.09 mg/L, mean OS: 42.05 vs. 42.83 months, respectively, P = 0.983, Fig 4D), N1 subgroup (n = 20, Cys-C ≤ 1.09 mg/L vs. > 1.09 mg/L, mean OS: 37.09 vs. 26.26 months, respectively, P = 0.160, Fig 4F), or M1 subgroup (n = 19, Cys-C ≤ 1.09 mg/L vs. > 1.09 mg/L, mean OS: 29.00 vs. 26.72 months, respectively, P = 0.655, Fig 4H).

The relationship of preoperative serum Cys-C with DFS of RCC patients

For DFS, we excluded the patients with pM1 classification (n = 19). 306 patients were enrolled to analyze the relationship of preoperative serum Cys-C with clinicopathologic characteristics. Univariate Cox proportional hazards regression model analysis showed that low serum Cys-C was an independent predictor favorable to DFS (P = 0.001), and BMI, pTNM stage, pT-status, pN-status, and ALP remained clinically and statistically significant predictors of prognosis (Table 6). Multivariate analysis was used to adjust the confounders of the association of preoperative serum Cys-C levels with disease progression. Considering the multicollinearity between pTNM stage and pT-status as well as pN-status, pTNM stage was not included in the multivariate analysis. The results showed that low serum Cys-C was a significantly independent predictor favorable to DFS (HR, 3.50; P = 0.013). In addition, the pN-status was also a clinically and statistically significant predictor of prognosis (Table 6).

Kaplan-Meier method and log-rank test were used to compare the different effects of serum Cys-C level on DFS. Patients with serum Cys-C ≤ 1.09 mg/L (n = 198) showed a significantly better DFS than patients with serum Cys-C > 1.09 mg/L (n = 75) (Cys-C ≤ 1.09 mg/L vs. > 1.09 mg/L, mean DFS: 71.95 vs. 58.10 months, respectively, P < 0.001, Fig 3B).

We compared survival curves of patients with low and high preoperative serum Cys-C at different pathological stages (pT-status, pN-status, pM-status) using Kaplan-Meier method and log-rank test. In stage I-II subgroup, patients with high serum Cys-C had a significantly poorer DFS than patients with low serum Cys-C patients (n = 273, Cys-C ≤ 1.09 mg/L vs. > 1.09 mg/L, mean OS: 71.95 vs. 58.10 months, respectively, P < 0.001, Fig 5A). In pT1-2 subgroup, patients with high serum Cys-C also had a significantly poorer DFS than patients with low serum Cys-C patients (n = 278, Cys-C ≤ 1.09 mg/L vs. > 1.09 mg/L, mean OS: 71.24 vs. 56.94 months, respectively, P < 0.001, Fig 5C). In the pN0 subgroup, patients with high serum

### Table 2: The analysis of three variables according to the receiver operating characteristic curve.

| Variable             | specificity | sensitivity | Optimal cutoff value | AUC   | The low 95% CI | The high 95% CI | P value |
|----------------------|-------------|-------------|----------------------|-------|---------------|----------------|---------|
| Preoperative Cystain-C | 0.71        | 0.65        | 1.09                 | 0.69  | 0.64          | 0.74           | <0.001  |
| Preoperative CRE      | 0.96        | 0.13        | 44.70                | 0.52  | 0.47          | 0.58           | 0.594   |
| Preoperative e-GFR    | 0.71        | 0.53        | 68.94                | 0.55  | 0.49          | 0.60           | 0.325   |

https://doi.org/10.1371/journal.pone.0178823.g001
Cys-C had poorer DFS than patients with low serum Cys-C (n = 293, Cys-C ≤ 1.09 mg/L vs. > 1.09 mg/L, mean OS: 71.38 vs. 57.93 months, respectively, P < 0.001, Fig 5E). However, there was no significance difference in DFS in stage III-IV (n = 33, Cys-C ≤ 1.09 mg/L vs. > 1.09 mg/L, mean OS: 32.38 vs. 42.36 months, respectively, P = 0.163, Fig 5B), pT3-4 n = 28, Cys-C ≤ 1.09 mg/L vs. > 1.09 mg/L, mean OS: 35.74 vs. 45.12 months, respectively, P = 0.301 Fig 5D), and pN1 (n = 13, Cys-C ≤ 1.09 mg/L vs. > 1.09 mg/L, mean OS: 26.28 vs. 18.99 months, respectively, P = 0.818, Fig 5F) groups.

### Discussion

This is the first study to analyze the relationship between preoperative serum Cys-C and the prognosis on RCC. Previous studies had found that elevated serum Cys-C is associated with poor prognosis of other cancer patients [16]. However, no study has explored to the prognostic value of serum Cys-C on RCC patients. Patients with preoperative high serum Cys-C (> 1.09 mg/L) had shorter OS and DFS than patients with low serum Cys-C (≤ 1.09 mg/L). The results of multivariate analysis demonstrated that preoperative serum Cys-C was an independent factor for predicting OS of RCC patients. In addition, preoperative serum Cys-C was also an independent factor for predicting DFS of non-metastatic RCC patients treated with complete surgical resection.

Analyses of relationship between serum Cys-C level and OS and DFS of patients at different stages (pTNM-stage, pT-stage, pN-stage and pM-stage) demonstrated that low preoperative serum Cys-C level was a favorable prognostic factor for OS of patients at pT1-2, pN0 and pM0 stages and DFS of patients at pT1-2 and pN0 stages, but had no statistically significant association with OS of patients at pT3-4, pN1 and pM1 stages and DFS of patients at pT3-4 and pN1 stages, probably due to insufficient number of patients at advanced stages.

As a member of cysteine protease inhibitors, Cys-C inhibits tumor invasion and metastasis. Downregulation of Cys-C is frequently reported in breast, prostate, stomach, uterus, colon, and non-small cell lung cancer tissues [19–22], but controversial in other cancers [23, 24]. Cys-C level is rarely detected or reduced in tumor tissues of RCC patients comparing that in
normal tissues [25]. Overall, Cys-C expression in cancer tissues indicates that Cys-C expression is primarily suppressed by tumorigenesis and decreased Cys-C level may induce tumor formation, invasion and metastasis.

Circulating Cys-C is also considered to function as a tumor suppressor [26]. However, contrast to the reduced Cys-C level in cancer tissues, serum Cys-C level is elevated in cancer

Table 4. Clinicopathological variables of patients stratified by preoperative serum cystatin-C.

| Characteristics          | Cystatin-C≤1.09 mg/L (n = 216) | Cystatin-C>1.09 mg/L (n = 109) | P-value  |
|--------------------------|---------------------------------|---------------------------------|----------|
| Age, (years)             | 49.00 (18.00–78.00)             | 56.00 (25.00–84.00)             | <0.001 a |
| BMI, (kg/m²)             | 23.44 (16.02–35.67)             | 23.62 (15.41–38.76)             | 0.592 a  |
| Gender                   |                                 |                                 | 0.008 b  |
| Male                     | 137 (63.40%)                    | 85 (78.00%)                     |          |
| Female                   | 79 (36.60%)                     | 24 (22.00%)                     |          |
| pT-stage                 |                                 |                                 | <0.001 b |
| pT1                      | 175 (81.00%)                    | 60 (55.00%)                     |          |
| pT2                      | 30 (13.90%)                     | 23 (21.10%)                     |          |
| pT3                      | 8 (3.70%)                       | 18 (16.50%)                     |          |
| pT4                      | 3 (1.40%)                       | 8 (7.30%)                       |          |
| pN-stage                 |                                 |                                 | 0.036 b  |
| pN0                      | 207 (95.80%)                    | 98 (89.90%)                     |          |
| pN1                      | 9 (4.20%)                       | 11 (10.10%)                     |          |
| pM-stage                 |                                 |                                 | 0.020 b  |
| pM0                      | 208 (96.30%)                    | 98 (89.90%)                     |          |
| pM1                      | 8 (3.70%)                       | 11 (10.10%)                     |          |
| pTNM-stage               |                                 |                                 | <0.001 b |
| I                        | 171 (79.20%)                    | 56 (51.40%)                     |          |
| II                       | 27 (12.50%)                     | 19 (17.40%)                     |          |
| III                      | 8 (3.70%)                       | 18 (16.50%)                     |          |
| IV                       | 10 (4.60%)                      | 16 (14.70%)                     |          |
| Fuhrman grade            |                                 |                                 | 0.005 b  |
| I                        | 36 (16.70%)                     | 11 (10.10%)                     |          |
| II                       | 103 (47.70%)                    | 53 (48.60%)                     |          |
| III                      | 16 (7.40%)                      | 21 (19.30%)                     |          |
| IV                       | 3 (1.40%)                       | 4 (3.70%)                       |          |
| Unknown                  | 58 (26.90%)                     | 20 (18.30%)                     |          |
| Pathological types       |                                 |                                 | 0.016 b  |
| Clear cell carcinoma     | 163 (75.50%)                    | 97 (89.00%)                     |          |
| Papillary carcinoma      | 16 (7.40%)                      | 4 (3.70%)                       |          |
| Others                   | 37 (17.10%)                     | 8 (7.30%)                       |          |
| Preoperative ALP (U/L)   | 70.90 (16.00–237.30)            | 77.90 (27.50–419.00)            | 0.002 a  |
| Preoperative TP (g/L)    | 72.67 (29.65–93.46)             | 72.75 (56.82–85.09)             | 0.481 a  |
| Preoperative CRE (μmol/L)| 70.85 (38.10–123.60)            | 84.60 (40.80–221.90)            | <0.001 a |
| Preoperative UA (μmol/L) | 347.95 (120.70–589.60)          | 378.70 (112.60–616.30)          | 0.008 a  |
| Preoperative e-GFR (mL/min/1.73 m²) | 83.33 (35.82–144.31)  | 65.66 (16.31–131.90) | <0.001 a |

Abbreviation: BMI: body mass index; ALP: alkaline phosphatase; TP: total protein; UA: uric acid; CRE: creatinine; e-GFR: estimated glomerular filtration rate.

a Kruskal-Wallis test
b Chi-square test

https://doi.org/10.1371/journal.pone.0178823.t004
patients and associated with their poor prognosis [27, 28]. In this study, we showed for the first time that serum Cys-C is elevated in RCC patients at pT3-4 stage than at pT1-2 stage, and in RCC patients at pM1 stage than at pM0 stage (Fig 2). Moreover, patients with high serum Cys-C level (>1.09 mg/L) at pT1-2, pN0 and pM0 stages had worse OS than patients with low serum Cys-C level (≤1.09 mg/L) at pT1-2, pN0 and pM0 stages, suggesting that serum Cys-C level could be a good prognostic biological marker for RCC patients.

As the major substrate of Cys-C, Cysteine cathepsin protease activity is frequently dysregulated in the context of neoplastic transformation [29, 30]. Increased activity and aberrant localization of proteases in tumor microenvironment have a potent role in driving cancer progression, proliferation, invasion and metastasis [31]. The elevated cathepsin expression is significantly associated with poor prognosis of patients with melanoma as well as breast, lung, head and neck, colorectal and many other cancers [32–34]. It has been shown that cathepsin D expression level was higher in RCC tumor tissues and urine than benign or normal volunteer samples [35, 36]. However, serum cathepsin D is not altered in RCC patients in comparison...
with healthy volunteers [37] and cathepsins B, C, H, L and S are not higher in RCC tissue than in normal kidney [38]. Although changes of cathepsins expression in RCC are controversial,

Table 5. Univariate and multivariate analyses in 325 patients with RCC for overall survival (OS).

| Variables                        | Univariate Analysis | Multivariate Analysis |
|----------------------------------|---------------------|-----------------------|
|                                  | HR                  | 95% CI                | P value | HR                  | 95% CI                | P value |
| Age, (years) continuous          | 1.01                | 0.99 to 1.04          | 0.338   | 1.02                | 0.99 to 1.02          | 0.140   |
| Gender                           | Male                | 1.00 (ref.)           |         | Female              | 1.15                | 0.62 to 2.16          | 0.656   |
|                                  | BMI                 | 0.86                  | 0.78 to 0.94 | 0.001   | 0.92                | 0.83 to 1.02          | 0.140   |
| Fuhrman grade                    | I                   | 1.00 (ref.)           |         | II                  | 2.33                | 0.53 to 10.19         | 0.261   |
|                                  | III                 | 8.41                  | 1.86 to 38.02 | 0.005   | 1.73                | 0.38 to 7.80          | 0.473   |
|                                  | IV                  | 16.43                 | 3.01 to 89.79 | 0.001   | 2.97                | 0.59 to 14.92         | 0.186   |
|                                  | unknown             | 3.59                  | 0.80 to 16.21 | <0.001  | 3.22                | 0.41 to 24.77         | 0.260   |
| Pathological types               | Clear cell carcinoma | 1.00 (ref.)           |         | Papillary carcinoma | 2.23                | 0.87 to 5.72          | 0.095   |
|                                  | Others              | 0.92                  | 0.36 to 2.36 | 0.870   |                     |                      |
| pTNM-stage                       | I                   | 1.00 (ref.)           |         | II                  | 1.63                | 0.53 to 5.05          | 0.398   |
|                                  | III                 | 7.72                  | 3.25 to 18.32 | <0.001  | 1.73                | 0.77 to 4.67          | 0.190   |
|                                  | IV                  | 22.61                 | 10.80 to 47.37 | <0.001  | 2.97                | 0.59 to 14.92         | 0.186   |
| pT-stage                         | pT1                 | 1.00 (ref.)           |         | pT2                 | 2.46                | 1.09 to 5.51          | 0.029   |
|                                  | pT3                 | 5.85                  | 2.61 to 13.14 | <0.001  | 1.90                | 0.77 to 4.67          | 0.190   |
|                                  | pT4                 | 14.18                 | 6.08 to 33.09 | <0.001  | 0.85                | 0.23 to 3.10          | 0.813   |
| pN-stage                         | pN0                 | 1.00 (ref.)           |         | pN1                 | 13.48               | 7.09 to 25.64         | <0.001  |
|                                  | pM-stage            | 1.00 (ref.)           |         | pM0                 | 1.00 (ref.)         | 1.00 (ref.)          |         |
|                                  | pM1                 | 14.89                 | 7.76 to 28.6 | <0.001  | 4.64                | 1.84 to 11.69         | 0.001   |
| Preoperative ALP, (U/L), continuous | 1.01               | 1.00 to 1.01          | <0.001  | 2.97                | 0.99 to 1.01         | 0.99 to 1.01         | 0.997   |
| Preoperative TP, (g/L), continuous | 1.02               | 0.97 to 1.07          | 0.386   | Preoperative CRE, (μmol/L), continuous | 1.00 | 0.99 to 1.01 | 0.651 |
| Preoperative UA, (μmol/L), continuous | 1.00               | 0.99 to 1.00          | 0.098   | Preoperative e-GFR, (mL/min/1.73 m²), continuous | 0.99 | 0.98 to 1.01 | 0.452 |
| Preoperative Cystatin-C <1.09 mg/L | 1.00 (ref.)         | 1.00 (ref.)          |         | Preoperative Cystatin-C ≥1.09 mg/L | 4.03 | 2.15 to 7.54 | <0.001 |
| Abbreviation: HR: hazard ratio; CI: confidence interval BMI: body mass index; ALP: alkaline phosphatase; TP: total protein; UA: uric acid; CRE: creatinine; e-GFR: estimated glomerular filtration rate; ref.: reference.  

"a" univariate cox regression analyses

"b" multivariate cox regression analyses.

https://doi.org/10.1371/journal.pone.0178823.t005
the balance between Cys-C and its substrates palain-like cysteine proteases is very important for tumor cell invasion and metastasis. Elevated serum Cys-C in RCC may be a reflection of increased level and activity of extracellular proteases (such as palain-like cysteine proteases and other EMC proteases) in tumors or the stromal host cells [39]. Therefore, the relation of RCC at high stage with increased serum Cys-C may be due to its more aggressive characteristics and higher proteases level. Elevated serum Cys-C level of cancer patients is not directly associated with the invasion of tumor cells into target organs, but represents a secondary effect due to a reduced elimination rate of Cys-C by glomeruli caused by disease-related kidney damages [40]. For example, higher stage RCC may damage more renal structure and function, therefore reducing GFR and increasing serum Cys-C.

Previous studies demonstrated serum Cys-C is an important biomarker of renal function and associated better with direct measures of glomerular filtration rate more precisely than CRE and e-GFR, because serum CRE is dependent not only on GFR, but also on body muscle mass, which are affected by age and sex, and the e-GFR in our study is calculated using creatinine clearance using serum CRE levels [41, 42]. Estimation of renal function is important since renal insufficiency is directly associated with increased mortality after cancer [43]. To explore the effect of renal function on prognosis, we also analyzed the association of serum Cys-C, CRE and e-GFR with the prognosis of RCC patients, respectively. Our results showed that serum Cys-C was a better prognostic indicator than CRE and e-GFR and that preoperative serum Cys-C rather than CRE and e-GFR is the prognostic factor for OS of RCC patients after surgery. Although some studies showed that end-stage renal disease would affect tumor prognosis, the association of early renal injury and cancer prognosis is not clear [44]. Our results showed that no patient died of end-stage renal disease, most possibly due to short follow-up time. In addition, our resulted also showed that preoperative serum Cys-C level was positively correlated with CRE, but negatively correlated with e-GFR. Therefore, regardless of the loss of renal function by renal structure destroy by tumor mass, serum Cys-C is still a predictor of RCC although the role of serum Cys-C in RCC progression needs to be further explored.

The study has some limitations. Firstly, it is a retrospective, single-center study, which may limit the prognostic value of serum Cys-C. Therefore, a large-scale prospective validation

Fig 3. Kaplan-Meier curves depicting overall survival (OS) of disease-free survival (DFS) of (A) 325 patients and (B) 306 patients (M0) with renal cell cancer according to their preoperative cystatin C level.

https://doi.org/10.1371/journal.pone.0178823.g003
Fig 4. Kaplan-Meier curves depicting overall survival (OS) of 325 patients with renal cell cancer stratified at different pT-status, pN-status, and pM-status according to their preoperative cystatin C level.
(A) Patients in I-II subgroup; (B) Patients in III-IV subgroup; (C) Patients in T1-2 subgroup; (D) Patients in T3-4 subgroup; (E) Patients in N0 subgroup; (F) Patients in N1 subgroup; (G) Patients in M0 subgroup; (H) Patients in M1 subgroup.

Table 6. Univariate and multivariate analyses in 306 patients with RCC for disease-free survival (DFS).

| Variables                  | Univariate Analysis | Multivariate Analysis |
|----------------------------|---------------------|-----------------------|
| Age, (years) continuous    | 1.01 0.98 to 1.04   | 0.457a                |
| Gender                     |                     |                       |
| Male                       | 1.00 (ref.)         |                       |
| Female                     | 0.99 0.48 to 2.04   | 0.985a                |
| BMI                        | 0.84 0.76 to 0.94   | 0.001a 0.93 0.81 to 1.05 | 0.263b |
| Fuhrman grade              |                     |                       |
| I                          | 1.00 (ref.)         | 1.00 (ref.)           |
| II                         | 1.39 0.39 to 4.86   | 0.610a 1.04 0.29 to 3.78 | 0.941b |
| III                        | 3.80 0.98 to 14.69  | 0.053a 2.57 0.58 to 11.41 | 0.212b |
| IV                         | 18.75 3.76 to 93.52 | <0.001a 21.99 3.92 to 123.29 | <0.001b |
| unknown                    | 1.79 0.48 to 6.76   | 0.388a 0.69 0.15 to 3.11 | 0.635b |
| Pathological types         |                     |                       |
| Clear cell carcinoma       | 1.00 (ref.)         |                       |
| Papillary carcinoma        | 1.79 0.54 to 5.91   | 0.338a                |
| Others                     | 0.84 0.29 to 2.41   | 0.750a                |
| pTNM-stage                 |                     |                       |
| I                          | 1.00 (ref.)         |                       |
| II                         | 2.53 0.95 to 6.75   | 0.063a                |
| III                        | 10.95 4.91 to 24.41 | <0.001a               |
| IV                         | 15.15 4.87 to 47.1  | <0.001a               |
| pT-stage                   |                     |                       |
| pT1                        | 1.00 (ref.)         | 1.00 (ref.)           |
| pT2                        | 2.68 1.13 to 6.31   | 0.024a 1.80 0.67 to 4.83 | 0.238b |
| pT3                        | 6.03 2.46 to 14.81  | <0.001a 1.02 0.32 to 3.20 | 0.972b |
| pT4                        | 12.16 4.03 to 36.75 | <0.001a 2.07 0.47 to 9.01 | 0.329b |
| pN-stage                   |                     |                       |
| pN0                        | 1.00 (ref.)         | 1.00 (ref.)           |
| pN1                        | 18.68 8.96 to 38.95 | <0.001a 16.24 to 48.22 | <0.001b |
| Preoperative ALP, (U/L)    | 1.01 1.00 to 1.01   | <0.001a 0.99 0.99 to 1.00 | 0.984b |
| Preoperative TP, (g/L)     | 1.02 0.96 to 1.08   | 0.515a                |
| Preoperative CRE, (μmol/L), continuous | 1.01 0.99 to 1.02 | 0.221a |
| Preoperative UA, (μmol/L), continuous | 1.00 0.99 to 1.00 | 0.415a |
| Preoperative e-GFR, (mL/min/1.73 m²), continuous | 0.99 0.97 to 1.01 | 0.179a |
| Preoperative Cystatin-C group |                     |                       |
| Preoperative Cystatin-C ≤1.09 mg/L | 1.00 (ref.)         | 1.00 (ref.)           |
| Preoperative Cystatin-C >1.09 mg/L | 3.76 1.88 to 7.51 | <0.001a 3.50 1.29 to 9.51 | 0.013b |

Abbreviation: HR: hazard ratio; CI: confidence interval BMI: body mass index; ALP: alkaline phosphatase; TP: total protein; UA: uric acid; CRE: creatinine; e-GFR: estimated glomerular filtration rate; ref.: reference.

a univariate cox regression analyses
b multivariate cox regression analyses.

https://doi.org/10.1371/journal.pone.0178823.t006
Fig 5. Kaplan-Meier curves depicting disease-free survival (DFS) according to preoperative cystatin C levels in 306 patients with renal cell cancer. Patients were stratified according to the pT-status, pN-status, and pM-status. (A) Kaplan-Meier analysis of DFS in I-II subgroup; (B) Kaplan-Meier analysis of DFS in III-IV subgroup. (C) Kaplan-Meier analysis of DFS in T1-2 subgroup. (D) Kaplan-Meier analysis of DFS in T3-4 subgroup. (E) Kaplan-Meier analysis of DFS in N0 subgroup. (F) Kaplan-Meier analysis of DFS in N1 subgroup.

https://doi.org/10.1371/journal.pone.0178823.g005
study is needed. Secondly, Cys-C differs among individuals and can be influenced by heterogeneity in the treatment used for the RCC patients after surgical resection, which led to different clinical prognosis; such therapeutic strategy should be considered in the future analysis. Thirdly, as the survival of early stage RCC patients is greatly extended, longer following time is needed to obtain a more reliable result. Lastly, our results still need multicenter validation.

Conclusions
In conclusion, our results revealed that preoperative serum Cys-C level could be considered as not only the renal function predictor, but also an independent prognostic factor for surgical RCC patients. This is also confirmed in RCC patients at early stages according to pT, pN and pM classifications. Overall, serum Cys-C may be a convenient and useful biomarker to distinguish RCC patients with high risk of recurrent or metastasis after surgery and RCC patients with higher serum Cys-C level should be more closely followed up.

Ethical approval
This retrospective study was approved by the Institute Research Medical Ethics Committee of Sun Yat-sen University Cancer Center. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. All included patients provided written informed consent and their information were recorded and registered in our cancer registry system.

Supporting information
S1 Table. Relevant data underlying the study.
(XLSX)

Author Contributions
Conceptualization: HH FJZ.
Data curation: SJG YFX QMH.
Formal analysis: SJG XBH KBG PD CG.
Methodology: KY GWY DC.
Software: ZSL XDL.
Supervision: ZKQ ZWL.
Validation: WJC.
Visualization: MZ.
Writing – original draft: SJG YFX XBH FJZ.
Writing – review & editing: QMH HH FJZ.

References
1.  Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016 2016-03-0 1; 66(2):115–32. https://doi.org/10.3322/caac.21338 PMID: 26808342
2.  Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016 2016-01-0 1; 66(1):7–30. https://doi.org/10.3322/caac.21332 PMID: 26742998
3. Jayson M, Sanders H. Increased incidence of serendipitously discovered renal cell carcinoma. UROLOGY 1998 1998-02-01; 51(2):203–5. PMID: 9495698

4. Luciani LG, Cestari R, Tallarigo C. Incidental renal cell carcinoma-age and stage characterization and clinical implications: study of 1092 patients (1982–1997). UROLOGY 2000 2000-07-01; 56(1):58–62. PMID: 10869624

5. Eggener SE, Yossepowitch O, Pettus JA, Snyder ME, Motzer RJ, Russo P. Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J CLIN ONCOL 2006 2006-07-01; 24(19):3101–6. https://doi.org/10.1200/JCO.2005.04.8280 PMID: 16809736

6. Kim SP, Alt AL, Weight CJ, Costello BA, Cheville JC, Lohse C, et al. Independent validation of the 2010 American Joint Committee on Cancer TNM classification for renal cell carcinoma: results from a large, single institution cohort. J Urol 2011 2011-06-01; 185(6):2035–9. https://doi.org/10.1016/j.juro.2011.02.059 PMID: 21496854

7. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. AM J SURG PATHO L 1982 1982-10-01; 6(7):655–63. PMID: 7180965

8. Volpe A, Patard JJ. Prognostic factors in renal cell carcinoma. WORLD J UROL 2010 2010-06-01; 28 (3):319–27. https://doi.org/10.1007/s00345-010-0540-8 PMID: 20364259

9. Filler G, Bokenkamp A, Hofmann W, Le Bricon T, Martinez-Bru C, Grubb A. Cystatin C as a marker of GFR—history, indications, and future research. CLIN BIOCHEM 2005 2005-01-01; 38(1):1–8. https://doi.org/10.1016/j.clinbiochem.2004.09.025 PMID: 15607309

10. Abrahamsson M, Dalboge H, Olafsson I, Carlsen S, Grubb A. Efficient production of native, biologically active human cystatin C by Escherichia coli. FEBS LETT 1988 1988-08-15; 236(1):14–8. PMID: 3042461

11. Randers E, Erlandsen EJ, Pedersen OL, Hasling C, Danielsen H. Serum cystatin C as an endogenous parameter of the renal function in patients with normal to moderately impaired kidney function. CLIN NEPHROL 2000 2000-09-01; 54(3):203–9. PMID: 11020018

12. Jovanovic D, Krstivojevic P, Obradovic I, Durdevic V, Dukanovic L. Serum cystatin C and beta2-microglobulin as markers of glomerular filtration rate. Ren Fail 2003 2003-01-01; 25(1):123–33. PMID: 12617340

13. Abrahamsson M, Alvarez-Fernandez M, Nathanson CM. Cystatins. Biochem Soc Symp 2003 2003-01-20(70):179–99.

14. Friedrich B, Jung K, Lein M, Turk I, Rudolph B, Hampel G, et al. Cathepsins B, H, L and cysteine protease inhibitors in malignant prostate cell lines, primary cultured prostatic cells and prostatic tissue. EUR J CANCER 1999 1999-01-01; 35(1):138–44. PMID: 10211102

15. Ebert E, Werle B, Julke B, Kopitar-Jeralja N, Kos J, Lah T, et al. Expression of cysteine protease inhibitors stefin A, stefin B, and cystatin C in human lung tumor tissue. ADV EXP MED BIOL 1997 1997-01-19; 421:259–65. PMID: 9330706

16. Kos J, Werle B, Lah T, Brunner N. Cysteine proteases and their inhibitors in extracellular fluids: markers for diagnosis and prognosis in cancer. Int J Biol Markers 2000 2000-01-01; 15(1):84–9. PMID: 10763147

17. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976 1976-01-19; 16(1):31–41. PMID: 1244564

18. Budczies J, Krauschen F, Sinn BV, Gyorffy B, Schmitt WD, Darb-Esfahani S, et al. CutoffFinder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLOS ONE 2012 2012-01-20; 7(12):e51862. https://doi.org/10.1371/journal.pone.0051862 PMID: 23251644

19. Werle B, Schanzenbacher U, Lah TT, Ebert E, Julke B, Ebert W, et al. Cystatins in non-small cell lung cancer: tissue levels, localization and relation to prognosis. ONCOL REP 2006 2006-10-01; 16(4):647–55. PMID: 16969475

20. Wegiel B, Jiborn T, Abrahamsson M, Helczynski L, Otterbein L, Persson JL, et al. Cystatin C is downregulated in prostate cancer and modulates invasion of prostate cancer cells via MAPK/Erk and androgen receptor pathways. PLOS ONE 2009 2009-01-20; 4(11):e7953. https://doi.org/10.1371/journal.pone.0007953 PMID: 19956729

21. Sokol JP, Schiemann WP. Cystatin C antagonizes transforming growth factor beta signaling in normal and cancer cells. MOL CANCER RES 2004 2004-03-01; 2(3):183–95. PMID: 15037657

22. Mori J, Tanikawa C, Funauchi Y, Lo PH, Nakamura Y, Matsuda K. Cystatin C as a p53-inducible apoptotic mediator that regulates cathepsin L activity. CANCER SCI 2016 2016-03-01; 107(3):298–306. https://doi.org/10.1111/cas.12881 PMID: 26757339
23. Zeng Q, Zhao Y, Yang Y, Zheng G, Wang G, Zhang P, et al. Expression of cystatin C in human esophageal cancer. TUMORI 2011 2011-03-01; 97(2):203–10. https://doi.org/10.1700/667.7784 PMID: 21617716

24. Zeng Q, Zhao Y, Yang Y, Chen XX, Wang G, Zhang P, et al. Expression of Cystatin C in human stomach neoplasms. MOL MED REP 2010 2010-07-01; 3(4):607–11. https://doi.org/10.3892/mmr_00000304 PMID: 21472286

25. Jacobsson B, Lignelid H, Bergerheim US. Transthyretin and cystatin C are catabolized in proximal tubular epithelial cells and the proteins are not useful as markers for renal cell carcinomas. HISTOPATHOL-OGY 1995 1995-06-01; 26(6):559–64. PMID: 7665147

26. Kolwijck E, Kos J, Obermajer N, Span PN, Thomas CM, Massuger LF, et al. The balance between extracellular cathepsins and cystatin C is of importance for ovarian cancer. EUR J CLIN INVEST 2010 2010-07-01; 40(7):591–9. https://doi.org/10.1111/j.1365-2362.2010.02305.x PMID: 20482593

27. Nelson H, Langer C, Herget-Rosenthal S, Wichert M, Assert R, Dohner H, et al. Prognostic significance of serum cystatin C in multiple myeloma. INT J HEMATOL 2012 2012-05-01; 95(5):545–50. https://doi.org/10.1007/s12185-012-1049-2 PMID: 22426688

28. Softic A, Begic L, Halilbasic A, Kos J. Cystatin C in sera of patients with aggressive non-Hodgkin B-cell lymphoma. Med Glas (Zenica) 2011 2011-02-01; 8(1):97–100.

29. Abrahamson M, Barrett AJ, Salvesen G, Grubb A. Isolation of six cysteine proteinase inhibitors from human urine. Their physicochemical and enzyme kinetic properties and concentrations in biological fluids. J BIOL CHEM 1986 1986-08-25; 261(24):11282–9. PMID: 3488317

30. Barrett AJ, Davies ME, Grubb A. The place of human gamma-trace (cystatin C) amongst the cysteine proteinase inhibitors. Biochem Biophys Res Commun 1984 1984-04-30; 120(2):631–6. PMID: 6203523

31. Olson OC, Joyce JA. Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response. NAT REV CANCER 2015 2015-12-01; 15(12):712–29. https://doi.org/10.1038/nrc4027 PMID: 26597527

32. Berdowska I. Cysteine proteases as disease markers. CLIN CHIM ACTA 2004 2004-04-01; 342(1–2):41–69. https://doi.org/10.1016/j.cca.2003.12.016 PMID: 15026265

33. Jedeszko C, Sloane BF. Cysteine cathepsins in human cancer. BIOL CHEM 2004 2004-11-01; 385(11):1017–27. https://doi.org/10.1515/BC.2004.132 PMID: 15576321

34. Zhang W, Wang S, Wang Q, Yang Z, Pan Z, Li L. Overexpression of cysteine cathepsin L is a marker of invasion and metastasis in ovarian cancer. ONCOL REP 2014 2014-03-01; 31(3):1334–42. https://doi.org/10.3892/or.2014.2967 PMID: 24402045

35. Merseburger AS, Hennenlotter J, Winter A, Beger G, Rinnab L, Kuczyk MA, et al. Cathepsin D expression in renal cell cancer-clinical implications. EUR UROL 2005 2005-09-01; 48(3):519–6. https://doi.org/10.1016/j.eururo.2005.03.019 PMID: 16115525

36. Vasudev NS, Sim S, Cairns DA, Ferguson RE, Craven RA, Stanley A, et al. Pre-operative urinary cathepsin D is associated with survival in patients with renal cell carcinoma. Br J Cancer 2009 2009-10-06; 101(7):1175–82. https://doi.org/10.1038/sj.bjc.6605250 PMID: 19789534

37. Merseburger AS, Hennenlotter J, Stenzl A, Beger G, Rinnab L, Kuczyk MA, et al. Cathepsin D serum levels are not a valid serum marker in renal cell carcinoma. UROL INT 2007 2007-01-20; 79(1):41–3. https://doi.org/10.1159/000102912 PMID: 17627167

38. Kirschke H, Clausen T, Gohring B, Gunther D, Heucke E, Laube F, et al. Concentrations of lysosomal cysteine proteases are decreased in renal cell carcinoma compared with normal kidney. J Cancer Res Clin Oncol 1997 1997-01-19; 123(7):402–6. PMID: 9260593

39. Magister S, Kos J. Cystatins in immune system. J CANCER 2013 2013-01-20; 4(1):45–56. https://doi.org/10.7150/jca.5044 PMID: 23386904

40. Stabuc B, Vrhovec L, Stabuc-Silh M, Cizej TE. Improved prediction of decreased creatinine clearance by serum cystatin C: use in cancer patients before and during chemotherapy. CLIN CHEM 2000 2000-02-01; 46(2):193–7. PMID: 10657375

41. Chen HH. Is cystatin C an important prognostic marker independent of renal function? J AM COLL CARDIOLOGY 2010 2010-11-30; 56(23):1937–8. https://doi.org/10.1016/j.jacc.2010.06.049 PMID: 21109117

42. Kumaresan R, Girin P. A comparison of serum cystatin C and creatinine with glomerular filtration rate in Indian patients with chronic kidney disease. Oman Med J 2011 2011-11-01; 26(6):421–5. https://doi.org/10.5001/omj.2011.107 PMID: 22253951

43. Launay-Vacher V, Janus N, Deray G. Renal insufficiency and cancer treatments. ESMO Open 2016 2016-01-20; 1(4):e91.

44. Yang Y, Li HY, Zhou Q, Peng ZW, An X, Li W, et al. Renal Function and All-Cause Mortality Risk Among Cancer Patients. Medicine (Baltimore) 2016 2016-05-01; 95(20):e3728.